Bicycle Therapeutics presents Phase 2 Duravelo-2 data showing comparable efficacy with improved safety

Zelenectide pevedotin combined with pembrolizumab demonstrated response rates comparable to standard of care in metastatic urothelial cancer with approximately four-fold lower skin reactions and half the peripheral neuropathy rates. The data validation of Bicycle's technology platform could support competitive positioning and potential label expansion in oncology.